Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

NeuClone Announces Preclinical Results for Stelara® (ustekinumab) Biosimilar Candidate

NeuClone
Posted on: 10 May 18
NeuClone Announces Preclinical Results for Stelara® (ustekinumab) Biosimilar Candidate

PR Newswire

SYDNEY, May 10, 2018

SYDNEY , May 10, 2018 /PRNewswire/ -- Biopharmaceutical company NeuClone has announced positive preclinical results of its biosimilar to Johnson & Johnson's Stelara®, including 3-dimensional (3-D) structure confirmation through X-ray crystallography analysis.

X-ray crystallography analysis confirms identity and equal structural integrity of NeuClone's biosimilar and the reference product Stelara®, in both primary amino acid sequence and 3-D folding (structure).

Stelara® is a monoclonal antibody that targets both interleukin-12 and -23 and is currently approved to treat various diseases including plaque psoriasis and Crohn's disease.

Dr Noelle Sunstrom, CEO of NeuClone, stated: "These results demonstrate our ability to create biosimilars using our Right from the Start® approach to biosimilarity, confirming each NeuClone product is indistinguishable from its originator at every stage of development. We develop crystals, functional cell-based assays and other tier 1 biosimilarity tests all in the same facility, allowing us to select the right candidate to go into the clinic."

NeuClone's Stelara® biosimilar is co-developed with Serum Institute of India and is currently in process scale up to support planned Phase I clinical trials in 2019. This will be the company's second product to enter clinical studies in Australia following its first product, a biosimilar of Roche / Genentech's Herceptin®.

In comparison to reference monoclonal antibody products, biosimilar approval requires more extensive analytical data packages to demonstrate structural and functional characterisation of the biosimilar candidate. Analytical studies, such as X-ray crystallography, provide the foundations for determining biosimilarity.

In 2017, Stelara® achieved global sales of USD 4.0 billion. EvaluatePharma has forecast global sales of Stelara® to reach USD 4.9 billion in 2022.

NeuClone representatives will attend the upcoming 2018 BIO International Convention in Boston from 4-7thJune 2018 and look forward to meeting potential commercialisation partners.

Stelara® is marketed by Janssen, a wholly owned subsidiary of Johnson & Johnson.

About NeuClone Pty. Ltd.

NeuClone Pty. Ltd. is a private biopharmaceutical company focused exclusively on developing a pipeline of biosimilar products. Five biosimilar products have been disclosed in NeuClone's pipeline that reference Herceptin®, Stelara®, Humira®, Synagis® and Prolia®/XGEVA®. NeuClone develops biosimilar products using its proprietary NeuMAX® platform that facilitates low-cost manufacture of biologics, whilst enabling the highest product quality. NeuClone is led by a highly experienced team with state-of-the-art integrated facilities based in Sydney, Australia. For more information, please visit www.neuclone.com.

Contact:
John Oksinski, Head of Global Business Development - j.oksinski@neuclone.com, +61429133767

View original content:http://www.prnewswire.com/news-releases/neuclone-announces-preclinical-results-for-stelara-ustekinumab-biosimilar-candidate-300646094.html

SOURCE NeuClone

PR Newswire
www.prnewswire.com

Last updated on: 10/05/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.